Kilitch Drugs (India) Limited Stock Price Today (NSE: KILITCH)
Fundamental Score
Kilitch Drugs (India) Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kilitch Drugs (India) Limited share price today is ₹201.32, down 3.74% on NSE/BSE as of 30 October 2026. Kilitch Drugs (India) Limited (KILITCH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹703.85 (Cr). The 52-week high for KILITCH share price is ₹267.90 and the 52-week low is ₹117.25. At a P/E ratio of 16.05x, KILITCH is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.52% and a debt-to-equity ratio of 0.32.
Kilitch Drugs (India) Limited Share Price Chart — NSE/BSE Historical Performance
Kilitch Drugs (India) Limited share price chart: 22.02% return over the past month. 52-week high ₹267.90, 52-week low ₹117.25.
Kilitch Drugs (India) Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹210.20 | ₹218.27 | ₹207.00 | ₹209.14 | 32.72K (Cr) | |
| ₹206.50 | ₹223.80 | ₹206.10 | ₹214.97 | 72.07K (Cr) | |
| ₹197.74 | ₹211.55 | ₹197.74 | ₹207.53 | 49.61K (Cr) | |
| ₹205.99 | ₹206.08 | ₹197.70 | ₹199.26 | 45.71K (Cr) | |
| ₹203.99 | ₹211.61 | ₹196.10 | ₹202.24 | 1.45L (Cr) | |
| ₹201.20 | ₹211.98 | ₹200.00 | ₹202.11 | 68.21K (Cr) | |
| ₹219.00 | ₹222.00 | ₹200.45 | ₹203.78 | 1.39L (Cr) | |
| ₹230.40 | ₹233.00 | ₹213.21 | ₹218.98 | 51.56K (Cr) | |
| ₹236.80 | ₹239.83 | ₹227.47 | ₹230.40 | 36.20K (Cr) | |
| ₹230.26 | ₹238.70 | ₹230.25 | ₹236.20 | 68.67K (Cr) |
Kilitch Drugs (India) Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹211.40 | ₹267.90 | ₹196.10 | ₹209.14 | -1.07% | |
| ₹175.50 | ₹232.50 | ₹166.15 | ₹213.32 | +21.55% | |
| ₹192.00 | ₹199.59 | ₹156.00 | ₹174.64 | -9.04% | |
| ₹195.81 | ₹207.77 | ₹168.00 | ₹186.59 | -4.71% | |
| ₹184.99 | ₹199.99 | ₹164.80 | ₹194.73 | +5.27% | |
| ₹154.02 | ₹197.00 | ₹145.50 | ₹182.39 | +18.42% | |
| ₹126.00 | ₹163.40 | ₹122.91 | ₹154.02 | +22.24% | |
| ₹160.00 | ₹165.00 | ₹117.25 | ₹124.45 | -22.22% | |
| ₹169.50 | ₹203.00 | ₹155.55 | ₹161.75 | -4.57% | |
| ₹173.43 | ₹184.10 | ₹154.30 | ₹156.98 | -9.49% | |
| ₹171.50 | ₹186.95 | ₹160.57 | ₹175.10 | +2.10% | |
| ₹195.40 | ₹201.38 | ₹169.23 | ₹171.05 | -12.46% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kilitch Drugs (India) Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kilitch Drugs (India) Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KILITCH across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (15.66%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (15.29%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 16.05 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (28.00% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (30.32% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (52.39% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (7.95x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.83)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (63.77%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-116.51 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.09%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kilitch Drugs (India) Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kilitch Drugs (India) Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Kilitch Drugs (India) LimitedKilitch Drugs (...Selected✓ KILITCH • 524500 | 58.9/100 | ₹201.32₹201 | ₹703.85₹703.85 | 16.05Average 16.1 Average | 12.52%Average 12.52% Average | 15.66%Good 15.66% Good | 0.32Excellent 0.3 Excellent | 52.39%Excellent 52.39% Excellent | 28.00%Excellent 28.00% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 71.6/100 | ₹1123.00₹1123 | ₹112075.40₹112075.40 | 25.03Average 25.0 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 53.5/100 | ₹2060.10₹2060 | ₹111296.90₹111296.90 | 101.68Average 101.7 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Zydus Lifesciences Limited share price112075.40 Cr
- Laurus Labs Limited share price111296.90 Cr
Kilitch Drugs (India) Limited PE Ratio History
Historical price-to-earnings ratio for KILITCH — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹16.60 | ₹175.10 | 10.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Kilitch Drugs (India) Limited Dividend History
Annual cash dividends paid by KILITCH — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹1.20 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Kilitch Drugs (India) Limited Quarterly Performance
Latest quarterly metrics for KILITCH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
4.03%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-3.73%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
28.00%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
52.39%
Compounded annual net profit growth over 5 years
Kilitch Drugs (India) Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KILITCH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Kilitch Drugs (India) Limited Financial Statements
Annual income statement, balance sheet and cash flow for Kilitch Drugs (India) Limited (KILITCH) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Kilitch Drugs (India) Limited
About KILITCH (Kilitch Drugs (India) Limited)
Kilitch Drugs India Ltd is a pharmaceutical enterprise carving a distinct niche in the global healthcare landscape. Focused on manufacturing and distributing a diverse portfolio of... specialized medications, Kilitch is committed to addressing critical healthcare needs worldwide. The company’s core strength lies in its state-of-the-art manufacturing facilities, meticulously designed to adhere to the stringent international quality standards. This focus enables the production of high-quality pharmaceuticals that are both safe and efficacious. Kilitch Drugs leverages its technical prowess and in-depth understanding of pharmaceutical science to deliver innovative solutions across various therapeutic segments. The company’s unwavering dedication to quality and its global reach positions it as a reliable partner in the pharmaceutical industry. Kilitch's product offerings are strategically curated to cater to a broad spectrum of medical requirements. The company specializes in sterile formulations, offering a wide range of injectable products including liquid and powder forms. These formulations are vital for delivering medications directly into the bloodstream, ensuring rapid and effective treatment. In addition to injectables, Kilitch provides advanced nasal delivery systems, enabling targeted administration of drugs through the nasal passages. Kilitch’s product line extends further to include topical formulations, addressing skin and surface-level ailments. This multi-faceted approach allows Kilitch to contribute to diverse therapeutic areas, strengthening its impact on global healthcare. Kilitch Drugs India Ltd. actively pursues opportunities for international expansion, strategically establishing its presence in key markets across the globe. By building strong distribution networks and fostering collaborations with local partners, Kilitch is successfully extending the reach of its pharmaceutical products. The company’s commitment to providing affordable, high-quality medications aligns with the growing demand for accessible healthcare solutions worldwide. Kilitch Drugs is poised to capitalize on emerging market trends and expanding its global footprint through strategic partnerships and a focus on product innovation. As Kilitch continues to evolve and grow, the company will maintain its unwavering commitment to improving patient outcomes.
Company Details
Key Leadership
KILITCH Share Price: Frequently Asked Questions
What is the current share price of Kilitch Drugs (India) Limited?
Kilitch Drugs (India) Limited (KILITCH) trades at ₹201.32 on NSE and BSE. Market cap ₹703.85 (Cr). Educational data only.
What is the P/E ratio of Kilitch Drugs (India) Limited?
Kilitch Drugs (India) Limited has a P/E of 16.05x vs industry average 34.89x.
What is the Bull Run score for Kilitch Drugs (India) Limited?
Kilitch Drugs (India) Limited has a Bull Run score of 58.9/100 based on 25+ financial parameters.
Does Kilitch Drugs (India) Limited pay dividends?
Kilitch Drugs (India) Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Kilitch Drugs (India) Limited?
Kilitch Drugs (India) Limited has ROE of 12.52%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kilitch Drugs (India) Limited?
Kilitch Drugs (India) Limited has debt-to-equity of 0.32.
Is Kilitch Drugs (India) Limited a good investment?
Bull Run gives Kilitch Drugs (India) Limited a score of 58.9/100. This is not investment advice — consult a SEBI-registered advisor.